Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Core Insights - Clearside Biomedical, Inc. is hosting a virtual key opinion leader (KOL) event on July 24, 2024, focusing on suprachoroidal drug delivery and its applications in treating wet age-related macular degeneration (AMD) [1][2] Company Overview - Clearside Biomedical is a biopharmaceutical company innovating the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) [8] - The company utilizes its patented SCS Microinjector® for targeted, non-surgical delivery of therapies to the macula, retina, or choroid, aiming to preserve and improve vision in patients with sight-threatening eye diseases [8] - Clearside's lead program, CLS-AX (axitinib injectable suspension), is currently in Phase 2b clinical testing for wet AMD [8] Event Details - The KOL event will feature presentations from leading retinal specialists, including David M. Brown, M.D., Glenn C. Yiu, M.D., Ph.D., and Victor Chong, M.D., MBA, followed by a live Q&A session [3][4][5] - The event aims to discuss the broad applicability of suprachoroidal drug delivery and ongoing clinical programs, as well as potential future development opportunities for Clearside [2][3] Expert Contributions - David M. Brown, M.D., is a prominent figure in retinal research, focusing on AMD and diabetic retinopathy, and holds multiple leadership roles in clinical research [4] - Glenn C. Yiu, M.D., Ph.D., is recognized for his work in ocular imaging technologies and gene editing related to retinal diseases, including pioneering studies on wet AMD [5] - Victor Chong, M.D., MBA, has extensive experience in retinal health and has held significant positions in leading pharmaceutical companies [6]